Laidlaw began coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note issued on Thursday. The firm set a “buy” rating and a $18.00 price target on the biopharmaceutical company’s stock. Laidlaw’s price objective points to a potential upside of 122.77% from the stock’s previous close.
Several other equities research analysts have also commented on the stock. ValuEngine lowered shares of Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. BidaskClub downgraded shares of Marinus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. Finally, JMP Securities reissued an “outperform” rating and set a $11.00 target price (up previously from $5.00) on shares of Marinus Pharmaceuticals in a research report on Tuesday, September 12th.
Marinus Pharmaceuticals (NASDAQ MRNS) opened at $8.08 on Thursday. Marinus Pharmaceuticals has a 12 month low of $0.82 and a 12 month high of $8.90.
A number of hedge funds have recently bought and sold shares of MRNS. Susquehanna International Group LLP acquired a new position in shares of Marinus Pharmaceuticals during the third quarter valued at $503,000. Iguana Healthcare Management LLC acquired a new position in shares of Marinus Pharmaceuticals in the 3rd quarter valued at $1,027,000. Perceptive Advisors LLC acquired a new position in shares of Marinus Pharmaceuticals in the 3rd quarter valued at $8,527,000. Granite Point Capital Management L.P. boosted its position in Marinus Pharmaceuticals by 250.3% during the 3rd quarter. Granite Point Capital Management L.P. now owns 2,684,848 shares of the biopharmaceutical company’s stock worth $15,760,000 after acquiring an additional 1,918,400 shares during the period. Finally, Citadel Advisors LLC boosted its position in Marinus Pharmaceuticals by 327.8% during the 3rd quarter. Citadel Advisors LLC now owns 51,383 shares of the biopharmaceutical company’s stock worth $301,000 after acquiring an additional 39,371 shares during the period. Institutional investors own 49.77% of the company’s stock.
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.